Which antitubercular drug metabolism is under genetic control –
First, I need to recall common antitubercular drugs and their metabolism. The main ones are isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin. Among these, I remember that isoniazid's metabolism is genetically determined. It's metabolized by acetylation, and people have different acetylator statuses—fast or slow. This affects how quickly the drug is processed and can influence both efficacy and side effects. For example, slow acetylators might have higher plasma levels, increasing the risk of toxicity like peripheral neuropathy.
Rifampin is metabolized by the liver, mainly through the cytochrome P450 system, but that's not genetically controlled in the same way. Pyrazinamide is metabolized in the liver but again, not as directly under genetic control as isoniazid. Ethambutol and streptomycin are excreted by the kidneys and through other pathways not as influenced by genetics. So the most likely answer here is isoniazid.
Now, the options weren't given, but the correct answer is probably option A, B, C, or D. Since the user's correct answer is supposed to be filled in, I'll assume that the correct option is the one corresponding to isoniazid. The key point is that isoniazid metabolism is acetylation-dependent and genetically determined by the N-acetyltransferase 2 (NAT2) enzyme. This genetic variation leads to different acetylator phenotypes.
For the explanation, I need to structure each section as per the user's instructions. Core concept would be about isoniazid's metabolism being under genetic control via NAT2. The correct answer explanation would delve into the acetylation process and its implications. The wrong options would be the other drugs and their metabolism pathways. Clinical pearl would highlight the importance of acetylator status in dosing.
Wait, the user mentioned the options are A to D but didn't list them. Maybe the original question had those letters assigned to the drugs. Since the correct answer is isoniazid, I'll proceed with that. Also, the user needs the correct answer line at the end. Let me make sure all sections are covered concisely without exceeding the character limit.
**Core Concept**
Genetic polymorphisms in the *N-acetyltransferase 2 (NAT2)* enzyme determine the rate of isoniazid metabolism. This leads to variable acetylator phenotypes (fast vs. slow), affecting drug efficacy and toxicity.
**Why the Correct Answer is Right**
Isoniazid is metabolized via hepatic acetylation catalyzed by NAT2. Genetic variants in the NAT2 gene (e.g., NAT2*5, NAT2*6) alter enzyme activity. Slow acetylators accumulate higher plasma isoniazid levels, increasing risks of peripheral neuropathy and hepatotoxicity. Fast acetylators may experience subtherapeutic drug levels.
**Why Each Wrong Option is Incorrect**
**Option A